FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

| OMB APPROVAL |
|--------------|
|              |

OMB Number: Estimated average burden hours per response: 0.5

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

|   | nd Address of   | Reporting Person <sup>*</sup>              |   |                             |                              |  |   |  | ker or Tra   |       | Symbol<br>CALS IN                  | <u>NC</u> [ 101       |  |  | all appli<br>Directo                                | cable)<br>or  |     | Owner      |
|---|---|--|---|-----------------------------|------------------------------|--|---|--|--|-------|------------------------------------|-----------------------|--|--|---|---|-----|------------|
|   | ,   | 1ACEUTICALS                                | (Middle)                                    |                             |                              | Date of /15/20   |   | t Trans  | saction (N   | Month | n/Day/Year)                        |                       |  | below) below)  |   |   |     |            |
| (Street)  |   |  | 92010                                       |                             | _ 4. If                      | 4. If Amendment, Date of Original Filed (Month/Day/Year) |   |  |  |       |                                    |                       | 6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person |  |   |   | son |            |
| (City)  | (S  | tate)                                      | (Zip)                                       |                             |                              |  |   |  |  |       |                                    |                       |  |  | Persor  | 1   |     |            |
|   |   | Tab  | le I - No                                   | on-Deriv                    | vative                       | Sec  | uritie  | s Ac   | quired   | , Dis | sposed o                           | of, or Be             | eneficia   | ally   | Owned   | ł   |     |            |
| 1. Title of Security (Instr. 3)                     |   | 2. Transaction<br>Date<br>(Month/Day/Year) |   | Execution Date, ear) if any |                              | 3.<br>Transaction<br>Code (Instr.<br>8)                  |   | 4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4 |  |       | and 5) Securit<br>Benefic<br>Owned |                       | ies<br>cially<br>Following   | 6. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 4)                      | 7. Nature<br>of Indirect<br>Beneficial<br>Ownership |   |     |            |
|   |   |  |   |                             |                              |  |   |  | Code   | v     | Amount                             | (A) or<br>(D)         | Price  |  | Reporte<br>Transac<br>(Instr. 3                     | d  unt of les sially less and 4)  0,839  0,839  0,839 |     | (Instr. 4) |
| Common  | Stock   |  |   | 03/15/                      | /2018                        | 0  | 3/15/2  | 018  | <b>M</b> <sup>(1)</sup>  |       | 900(1)                             | A                     | \$24.  | 42   | 10  | ,839  | D   |            |
| Common  | Stock   |  |   | 03/15/                      | /2018                        | 0  | 3/15/2  | 018  | <b>S</b> <sup>(1)</sup>  |       | 900(1)                             | D                     | \$50.4   | <b>5</b> <sup>(2)</sup>  | 9,  | 939   | D   |            |
| Common  | Stock   |  |   | 03/15/                      | /2018                        | 0  | 3/15/2  | 018  | M <sup>(1)</sup>   |       | 900(1)                             | A                     | \$24.  | 42   | 10,839<br>9,939                                     |   | D   |            |
| Common  | Stock   |  |   | 03/15/                      | /2018                        | 0  | 3/15/2  | 018  | <b>S</b> <sup>(1)</sup>  |       | 900(1)                             | D                     | \$51.5   | <b>9</b> (3)   |   |   | D   |            |
| Common  | Stock   |  |   | 03/15/                      | /2018                        | 0  | 3/15/2  | 018  | <b>M</b> <sup>(1)</sup>  |       | 200(1)                             | A                     | \$24.  | 42   | 10  | ,139  | D   |            |
| Common  | Stock   |  |   | 03/15/                      | /2018                        | 0  | 3/15/2  | 018  | S <sup>(1)</sup>   |       | 200(1)                             | D                     | \$52.1   | 1 <sup>(4)</sup>   | 9,  | 939   | D   |            |
| Common  | Stock   |  |   |                             |                              |  |   |  |  |       |                                    |                       |  |  | 1   | .00   | I   | By son     |
|   |   | ٦  | able II                                     |                             |                              |  |   |  |  |       | osed of<br>converti                | •                     |  | •  | wned  |   | ,   | •          |
| 1. Title of<br>Derivative<br>Security<br>(Instr. 3) | 2.<br>Conversion<br>or Exercise<br>Price of<br>Derivative<br>Security | 3. Transaction<br>Date<br>(Month/Day/Year) | 3A. Deer<br>Execution<br>if any<br>(Month/I | ned                         | 4.<br>Transa<br>Code (<br>8) | ction  | 5. Num<br>of<br>Deriva<br>Securi<br>Acquii<br>(A) or<br>Dispos<br>of (D)<br>(Instr.<br>and 5) | nber<br>ative<br>ities<br>red<br>sed                       | options, convertible securi  Date Exercisable and Expiration Date Month/Day/Year)  7. Title and Amount of Securities Underlying Derivative Se (Instr. 3 and 4) |       | nd<br>of<br>s<br>ng<br>e Security  | 8.<br>De<br>Se<br>(Ir | Price of<br>erivative<br>ecurity<br>nstr. 5)   | derivative<br>Securities<br>Beneficial<br>Owned<br>Following<br>Reported<br>Transactio | Ownersh Form: Direct (D) or Indirect (I) (Instr.    | Beneficial<br>Ownership<br>ct (Instr. 4)              |     |            |
|   |   |  |   |                             | Code                         | v  | (A)   |  | Date<br>Exercisa   |       | Expiration<br>Date                 | Title                 | Amoun<br>or<br>Numbe<br>of<br>Shares   |  |   |   |     |            |
| Employee<br>Stock<br>Option<br>(right to            | \$24.42   | 03/15/2018                                 | 03/15                                       | 5/2018                      | M                            |  | 2,000   |  | 07/01/20   | 20    | 06/30/2026                         | Common<br>Stock       | 2,000  |  | \$0   | 2,000   | D   |            |

## **Explanation of Responses:**

- 1. Acquired as a result of exercising a stock option pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was effective pursuant to Rule 10b5-1 Trading Plan adopted by the reporting person on 10/11/2017.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$49.97 to \$50.95, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4.
- 3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$51.00 to \$51.85, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) on this Form 4.
- 4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$52.03 to \$52.18, inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc., any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (4) on this Form 4.

## Remarks:

/s/Patrick R. O'Neil, attorney-

03/15/2018

in-fact

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.